Akèy › Kansè vejik › Maryland › Baltimore
Etid klinik pou Kansè vejik nan Baltimore, MD
24 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Ap rekriteFaz 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 2 plis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Johns Hopkins University, Baltimore
DK222 Study at Hopkins
Ap rekriteFaz 1
- Johns Hopkins Hospital, Baltimore
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
- Oncology Research Pharmacy and lnvestigational Drug Service, Baltimore
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Johns Hopkins Hospital, Baltimore
- ak 2 plis
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Ap rekriteFaz 3
- Johns Hopkins University ( Site 0843), Baltimore
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- Johns Hopkins Hospital, Baltimore
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- Anne Arundel Urology, Annapolis · 22 mi lwen
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Johns Hopkins Kimmel Cancer Center, Baltimore
Measuring Surgical Recovery After Radical Cystectomy
Ap rekriteEtid obsèvasyon
- John Hopkins Medical Institutions, Baltimore
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- John Hopkins Hospital, Baltimore
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Ap rekriteFaz 2/3
- Johns Hopkins Hospital, Baltimore
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- The John Hopkins Hospital, Baltimore
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Ap rekriteFaz 2
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore
Bladder EpiCheck Product Development Study
Ap rekriteEtid obsèvasyon
- Chesapeake Urology Research Associates, Towson · 8 mi lwen
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Renal Retention in High Grade Upper Tract Urothelial Cancer
Ap rekriteFaz 2
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore
Image-Guided Gynecologic Brachytherapy
Ap rekrite
- The SKCCC at Johns Hopkins, Baltimore
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- Johns Hopkins Medicine, Baltimore
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Ap rekrite
- Johns Hopkins Hospital, Baltimore
- Johns Hopkins Hospital, Baltimore
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Ap rekriteFaz 3
- Johns Hopkins University School of Medicine, Baltimore
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Ap rekrite
- Johns Hopkins Hospital, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi lwen
Gender Related Coping and Survivorship for Genitourinary Cancers
Ap rekriteEtid obsèvasyon
- Johns Hopkins Hospital, Baltimore
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Boston, MA26 etid
- Washington, DC26 etid
- Los Angeles, CA24 etid
- St. Louis, MO22 etid
- Philadelphia, PA21 etid
- Seattle, WA21 etid
- Edison, NJ21 etid
- Chicago, IL21 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè nan tete47 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè kolorektal31 etid
- Kansè pankreyas31 etid
- Kansè Metastatik28 etid
- Obèsite25 etid
- Ensifizyans kadyak24 etid
- Akidan serebavaskilè22 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.